154 related articles for article (PubMed ID: 15853706)
21. New progesterone derivatives as inhibitors of 5alpha-reductase enzyme and prostate cancer cell growth.
Cabeza M; Bratoeff E; Heuze I; Rojas A; Terán N; Ochoa M; Ramírez-Apan T; Ramírez E; Pérez V; Gracia I
J Enzyme Inhib Med Chem; 2006 Aug; 21(4):371-8. PubMed ID: 17059168
[TBL] [Abstract][Full Text] [Related]
22. Fungi test for evaluation of new antiandrogenic molecule.
Cabeza M; Quiroz A; Bratoeff E; Heuze I; Ramírez E; Murillo E
Proc West Pharmacol Soc; 2000; 43():29-30. PubMed ID: 11056949
[TBL] [Abstract][Full Text] [Related]
23. The enzyme and inhibitors of 4-ene-3-oxosteroid 5 alpha-oxidoreductase.
Li X; Chen C; Singh SM; Labrie F; Labire F [corrected to Labrie F]
Steroids; 1995 Jun; 60(6):430-41. PubMed ID: 7676475
[TBL] [Abstract][Full Text] [Related]
24. In vivo and in vitro effect of novel 4,16-pregnadiene-6,20-dione derivatives, as 5alpha-reductase inhibitors.
Bratoeff E; Cabeza M; Pérez-Ornelas V; Recillas S; Heuze I
J Steroid Biochem Mol Biol; 2008 Sep; 111(3-5):275-81. PubMed ID: 18644453
[TBL] [Abstract][Full Text] [Related]
25. Relative binding affinity of novel steroids to androgen receptors in hamster prostate.
Cabeza M; Heuze I; Sánchez M; Bratoeff E; Ramírez E; Rojas A; Orozco A; Mungía A; Agustín G; Cuatepotzo L; Gonzalez C; Palma S; Padilla D; Perez V; Jimenez G
J Enzyme Inhib Med Chem; 2005 Aug; 20(4):357-64. PubMed ID: 16206830
[TBL] [Abstract][Full Text] [Related]
26. Synthesis and pharmacological evaluation of new progesterone esters as 5alpha-reductase inhibitors.
Ramírez E; Cabeza M; Bratoeff E; Heuze I; Pérez V; Valdez D; Ochoa M; Teran N; Jimenez G; Ramírez T
Chem Pharm Bull (Tokyo); 2005 Dec; 53(12):1515-8. PubMed ID: 16327180
[TBL] [Abstract][Full Text] [Related]
27. Activity of steroid 4 and derivatives 4a-4f as inhibitors of the enzyme 5α-reductase 1.
Arellano Y; Bratoeff E; Heuze Y; Bravo M; Soriano J; Cabeza M
Bioorg Med Chem; 2018 Aug; 26(14):4058-4064. PubMed ID: 30007568
[TBL] [Abstract][Full Text] [Related]
28. Inhibition of androgen synthesis in human testicular and prostatic microsomes and in male rats by novel steroidal compounds.
Nnane IP; Kato K; Liu Y; Long BJ; Lu Q; Wang X; Ling YZ; Brodie A
Endocrinology; 1999 Jun; 140(6):2891-7. PubMed ID: 10342882
[TBL] [Abstract][Full Text] [Related]
29. Androgen metabolism in the prostate of the finasteride-treated, adult rat: a possible explanation for the differential action of testosterone and 5 alpha-dihydrotestosterone during development of the male urogenital tract.
George FW
Endocrinology; 1997 Mar; 138(3):871-7. PubMed ID: 9048585
[TBL] [Abstract][Full Text] [Related]
30. Novel C-17-heteroaryl steroidal CYP17 inhibitors/antiandrogens: synthesis, in vitro biological activity, pharmacokinetics, and antitumor activity in the LAPC4 human prostate cancer xenograft model.
Handratta VD; Vasaitis TS; Njar VC; Gediya LK; Kataria R; Chopra P; Newman D; Farquhar R; Guo Z; Qiu Y; Brodie AM
J Med Chem; 2005 Apr; 48(8):2972-84. PubMed ID: 15828836
[TBL] [Abstract][Full Text] [Related]
31. Novel 17 substituted pregnadiene derivatives as 5 alpha-reductase inhibitors and their binding affinity for the androgen receptor.
Cabeza M; Flores E; Heuze I; Sánchez M; Bratoeff E; Ramírez E; Francolugo VA
Chem Pharm Bull (Tokyo); 2004 May; 52(5):535-9. PubMed ID: 15133203
[TBL] [Abstract][Full Text] [Related]
32. Activity of 17beta-(N-alkyl/arylformamido) and 17beta-[(N-alkyl/aryl) alkyl/arylamido]-4-methyl-4-aza-5alpha-androstan-3-ones as 5alpha-reductase inhibitors in the hamster flank organ and ear.
Chen C; Li X; Singh SM; Labrie F
J Invest Dermatol; 1998 Aug; 111(2):273-8. PubMed ID: 9699729
[TBL] [Abstract][Full Text] [Related]
33. Novel 17-azolyl steroids, potent inhibitors of human cytochrome 17 alpha-hydroxylase-C17,20-lyase (P450(17) alpha): potential agents for the treatment of prostate cancer.
Njar VC; Kato K; Nnane IP; Grigoryev DN; Long BJ; Brodie AM
J Med Chem; 1998 Mar; 41(6):902-12. PubMed ID: 9526564
[TBL] [Abstract][Full Text] [Related]
34. Design and synthesis of novel steroidal imidazoles as dual inhibitors of AR/CYP17 for the treatment of prostate cancer.
Hou Q; He C; Lao K; Luo G; You Q; Xiang H
Steroids; 2019 Oct; 150():108384. PubMed ID: 30885648
[TBL] [Abstract][Full Text] [Related]
35. Synthesis and Study of Some 17a-aza-D-homo Steroids as 5α-Reductase Inhibitors.
Rana P; Dhingra N; Arora P; Dhingra R; Monika C; Gupta A
Curr Drug Discov Technol; 2021; 18(5):e22092020186180. PubMed ID: 32962621
[TBL] [Abstract][Full Text] [Related]
36. Effects of 5 alpha reductase inhibitors on androgen-dependent human prostatic carcinoma cells.
Festuccia C; Angelucci A; Gravina GL; Muzi P; Vicentini C; Bologna M
J Cancer Res Clin Oncol; 2005 Apr; 131(4):243-54. PubMed ID: 15650886
[TBL] [Abstract][Full Text] [Related]
37. New steroidal lactones as 5α-reductase inhibitors and antagonists for the androgen receptor.
Garrido M; Bratoeff E; Bonilla D; Soriano J; Heuze Y; Cabeza M
J Steroid Biochem Mol Biol; 2011 Nov; 127(3-5):367-73. PubMed ID: 21782943
[TBL] [Abstract][Full Text] [Related]
38. Dihydrotestosterone and the concept of 5alpha-reductase inhibition in human benign prostatic hyperplasia.
Bartsch G; Rittmaster RS; Klocker H
Eur Urol; 2000 Apr; 37(4):367-80. PubMed ID: 10765065
[TBL] [Abstract][Full Text] [Related]
39. Effects of novel 17-azolyl compounds on androgen synthesis in vitro and in vivo.
Nnane IP; Njar VC; Liu Y; Lu Q; Brodie AM
J Steroid Biochem Mol Biol; 1999 Dec; 71(3-4):145-52. PubMed ID: 10659703
[TBL] [Abstract][Full Text] [Related]
40. A new look at the 5alpha-reductase inhibitor finasteride.
Finn DA; Beadles-Bohling AS; Beckley EH; Ford MM; Gililland KR; Gorin-Meyer RE; Wiren KM
CNS Drug Rev; 2006; 12(1):53-76. PubMed ID: 16834758
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
